YOLT-101
Phase 1Small molecule
YOLT-101 is one of 33 small molecule programs targeting Familial Hypercholesterolemia. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Familial Hypercholesterolemia
#DrugCompanyPhaseTrials
1Niacor
AbbVieApproved
Leqvio
NovartisPhase 3
Lescol
NovartisPhase 3
Crestor
AstraZenecaPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Zocor
OOrganon and Co
Phase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Tricor
JJagotec
Phase 3
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Familial Hypercholesterolemia2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YOLT-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RRenJi Hospital